GLAXO Stock Overview
GlaxoSmithKline Pakistan Limited manufactures and markets research based specialties and pharmaceutical products in Pakistan and internationally.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 1/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
GlaxoSmithKline Pakistan Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | PK₨91.83 |
52 Week High | PK₨97.50 |
52 Week Low | PK₨68.00 |
Beta | 0.36 |
1 Month Change | 8.07% |
3 Month Change | 14.59% |
1 Year Change | 20.83% |
3 Year Change | -39.81% |
5 Year Change | -20.83% |
Change since IPO | 205.27% |
Recent News & Updates
Recent updates
Shareholder Returns
GLAXO | PK Pharmaceuticals | PK Market | |
---|---|---|---|
7D | -2.3% | -1.6% | 0.2% |
1Y | 20.8% | 35.4% | 57.6% |
Return vs Industry: GLAXO underperformed the PK Pharmaceuticals industry which returned 35.4% over the past year.
Return vs Market: GLAXO underperformed the PK Market which returned 57.6% over the past year.
Price Volatility
GLAXO volatility | |
---|---|
GLAXO Average Weekly Movement | 5.1% |
Pharmaceuticals Industry Average Movement | 5.8% |
Market Average Movement | 5.2% |
10% most volatile stocks in PK Market | 8.4% |
10% least volatile stocks in PK Market | 3.3% |
Stable Share Price: GLAXO has not had significant price volatility in the past 3 months.
Volatility Over Time: GLAXO's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2001 | 1,700 | Erum Rahim | www.pk.gsk.com |
GlaxoSmithKline Pakistan Limited manufactures and markets research based specialties and pharmaceutical products in Pakistan and internationally. It deals in anti-infective, dermatology, respiratory, analgesics, immunology, oncology, urology, vaccines, and analgesics therapy areas. The company sells its products under the Augmentin, Velosef, Amoxil, Dermovate, Clobevate, Betnovate, Cutivate, Calpol, Boostrix, Rotarix, Havrix, and Synflorix.
GlaxoSmithKline Pakistan Limited Fundamentals Summary
GLAXO fundamental statistics | |
---|---|
Market cap | PK₨29.24b |
Earnings (TTM) | PK₨533.95m |
Revenue (TTM) | PK₨49.66b |
54.8x
P/E Ratio0.6x
P/S RatioIs GLAXO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
GLAXO income statement (TTM) | |
---|---|
Revenue | PK₨49.66b |
Cost of Revenue | PK₨46.25b |
Gross Profit | PK₨3.42b |
Other Expenses | PK₨2.88b |
Earnings | PK₨533.95m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 1.68 |
Gross Margin | 6.88% |
Net Profit Margin | 1.08% |
Debt/Equity Ratio | 2.6% |
How did GLAXO perform over the long term?
See historical performance and comparison